VanEck Pharmaceutical ETF
114 hedge funds and large institutions have $510M invested in VanEck Pharmaceutical ETF in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 10 closing their positions.
698% more call options, than puts
Call options by funds: $3.29M | Put options by funds: $412K
300% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 10
33% more funds holding
Funds holding: 86 → 114 (+28)
19% more capital invested
Capital invested by funds: $427M → $510M (+$83.3M)
10.69% more ownership
Funds ownership: 77.28% → 87.97% (+11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$25.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$15.9M |
| 3 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$11.2M |
| 4 |
VAS
Valicenti Advisory Services
Elmira,
New York
|
+$5.31M |
| 5 |
AF
Alerus Financial
Grand Forks,
North Dakota
|
+$3.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$18.4M |
| 2 |
NI
Noked Israel
Ramat Hasharon,
Israel
|
-$9.41M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.18M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.48M |
| 5 |
HF
HRT Financial
New York
|
-$3.02M |
PPH Hedge Fund Activity: Q4 2022 in Review
114 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2022, worth a combined $510M — up 19% from $427M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PPH positions and 10 closed out — a net gain of 30 holders — while 22 added to existing stakes and 25 trimmed.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $25.4M. The largest seller was Goldman Sachs, cutting an estimated $18.4M.
- 114 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2022, up from 86 in Q3 2022.
- Funds reported $510M of VanEck Pharmaceutical ETF stock for Q4 2022, up 19% quarter-over-quarter.
- 40 funds opened new VanEck Pharmaceutical ETF positions in Q4 2022 and 10 closed out, a net change of +30 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $25.4M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2022 was Goldman Sachs, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2022.